, Institute of Medicine (US

J. E. Joy, . Wsj, and J. A. Benson, Copyright 1999 by the National Academy of Sciences. All rights reserved, p.288, 1999.

O. Indian-hemp and O. R. Gunjah, Provencial medical journal and retrospect of the medical sciences, 1843.

E. Meiri, H. Jhangiani, and J. J. Vredenburgh, Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting. Current medical research and opinion, vol.23, pp.533-576, 2007.

N. B. Finnerup, N. Attal, and S. Haroutounian, Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis, The Lancet Neurology, vol.14, pp.162-73, 2015.

, Addiction EMCfDaD. Cannabis legislation in Europe

, Publications Office of the European Union, 2017.

B. Wilsey, J. H. Atkinson, M. Td, and G. I. , The Medicinal Cannabis Treatment Agreement: Providing Information to Chronic Pain Patients Through a Written Document, The Clinical journal of pain, vol.31, pp.1087-96, 2015.

. D. Ph and . Ha, Renseignements destinés aux professionnels de la santé

, Le cannabis (marihuana, marijuana) et les cannabinoïdes. Santé Canada Date de la version la plus récente : février, 2013.

K. B. Svendsen, T. S. Jensen, and F. W. Bach, Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial, Bmj, vol.329, p.253, 2004.

J. Weber, M. Schley, and M. Casutt, Tetrahydrocannabinol (Delta 9-THC) Treatment in Chronic Central Neuropathic Pain and Fibromyalgia Patients: Results of a Multicenter Survey, 2009.

Y. Fedotov, E. Director, and C. Unooda, MARKET ANALYSIS OF PLANTBASED DRUGS

. Opiates, UNODC: United Nation Office on Drugs and Crime, Reports WD, 2017.

F. Grotenhermen, Medicinal uses of Marijuana and cannabinoids. Critical reviews in plant sciences, 2017.

M. A. Bachhuber, B. Saloner, C. Co, and C. L. Barry, Medical cannabis laws and opioid analgesic overdose mortality in the United States, JAMA internal medicine, vol.174, pp.1668-73, 1999.

, Cette enquête est un premier état des lieux de la prescription de dronabinol en France

, Une information spécifique des patients et une formation des professionnels de santé seront nécessaire afin d'éviter des prescriptions déraisonnées, Les thérapeutiques à base de cannabis nécessiteraient des études cliniques en France pour différentes indications afin d'être utilisées par les patients et les médecins dans de bonnes conditions

J. E. Joy, . Wsj, J. A. Benson, . Marijuana, and . Medicine, Copyright 1999 by the National Academy of Sciences. All rights reserved., 1999, p.288. 2. The leading source for pros &

O. Indian-hemp and O. R. Gunjah, Provencial medical journal and retrospect of the medical sciences, 1843.

J. E. Cosnett, . Dr, O. William-brooke, and . Shaughnessy, the old Limerick Journal, 1992.

P. Editors, C. Shultz, I. I. Luc, R. Benton, L. et al., Proceedings of the 40th Annual Macromarketing Conference, p.125, 2015.

, Addiction EMCfDaD. Cannabis legislation in Europe

, Publications Office of the European Union, 2017.

Y. Fedotov, E. Director, and C. Unooda, MARKET ANALYSIS OF PLANTBASED DRUGS

. Opiates, UNODC: United Nation Office on Drugs and Crime, Reports WD, 2017.

F. Grotenhermen, Medicinal uses of Marijuana and cannabinoids. Critical reviews in plant sciences, 2017.

, Therapeutic Goods Act, Prepared by the Office of Parliamentary Counsel C, vol.21, 1989.

, Compilation No 68. Act No. 47, 2017.

D. I. Abrams, J. F. Hilton, and R. J. Leiser, Short-term effects of cannabinoids in patients with HIV-1 infection: a randomized, placebo-controlled clinical trial, Annals of internal medicine, vol.139, pp.258-66, 2003.

J. Weber, M. Schley, and M. Casutt, Tetrahydrocannabinol (Delta 9-THC) Treatment in Chronic Central Neuropathic Pain and Fibromyalgia Patients: Results of a Multicenter Survey, 2009.

I. Obradovic, Législations relatives à l'usage et à la détention de cannabis : définitions et état des lieux en Europe, Observatoire Français des drogues et des toxicomanies (OFDT)

L. E. Klumpers, T. L. Beumer, and J. G. Van-hasselt, Novel Delta(9)tetrahydrocannabinol formulation Namisol(R) has beneficial pharmacokinetics and promising pharmacodynamic effects, British journal of clinical pharmacology, vol.74, pp.42-53, 2012.

E. P. Baron, Comprehensive Review of Medicinal Marijuana, Cannabinoids, and Therapeutic Implications in Medicine and Headache: What a Long Strange Trip It's Been, Headache, vol.55, pp.885-916, 2015.

R. G. Pertwee, Cannabinoid pharmacology: the first 66 years, British journal of pharmacology, vol.147, issue.1, pp.163-71, 2006.

. D. Ph and . Ha, Renseignements destinés aux professionnels de la santé

, Le cannabis (marihuana, marijuana) et les cannabinoïdes. Santé Canada Date de la version la plus récente : février, 2013.

L. Porta, C. Bura, S. A. Negrete, R. Maldonado, and R. , Involvement of the endocannabinoid system in osteoarthritis pain. The European journal of neuroscience, vol.39, pp.485-500, 2014.

L. M. Borgelt, K. L. Franson, A. M. Nussbaum, and G. S. Wang, The pharmacologic and clinical effects of medical cannabis, Pharmacotherapy, vol.33, pp.195-209, 2013.

L. Zuurman, A. E. Ippel, M. E. Van-gerven, and J. M. , Biomarkers for the effects of cannabis and THC in healthy volunteers, British journal of clinical pharmacology, vol.67, pp.5-21, 2009.

P. F. Whiting, R. F. Wolff, and S. Deshpande, Cannabinoids for Medical Use: A Systematic Review and Meta-analysis, Jama, vol.313, pp.2456-73, 2015.

K. H. Yang, D. Isaev, M. Morales, G. Petroianu, S. Galadari et al., The effect of Delta9-tetrahydrocannabinol on 5-HT3 receptors depends on the current density, Neuroscience, vol.171, pp.40-49, 2010.

L. Centre-de, Référence sur les Agents Tératogènes, 2017.

E. Meiri, H. Jhangiani, and J. J. Vredenburgh, Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting. Current medical research and opinion, vol.23, pp.533-576, 2007.

M. Duran, E. Perez, and S. Abanades, Preliminary efficacy and safety of an oromucosal standardized cannabis extract in chemotherapy-induced nausea and vomiting, British journal of clinical pharmacology, vol.70, pp.656-63, 2010.

. Société-française-d'étude, . De, and . De, , 2017.

N. B. Finnerup, N. Attal, and S. Haroutounian, Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis, The Lancet Neurology, vol.14, 2015.

M. H. Andreae, G. M. Carter, and N. Shaparin, Inhaled Cannabis for Chronic Neuropathic Pain: A Meta-analysis of Individual Patient Data, The journal of pain : official journal of the American Pain Society, vol.16, pp.1221-1253, 2015.

M. A. Ware, T. Wang, S. Shapiro, J. P. Collet, and . Team-cs, Cannabis for the Management of Pain: Assessment of Safety Study (COMPASS). The journal of pain : official journal of the, American Pain Society, vol.16, pp.1233-1275, 2015.

S. A. Gruber, K. A. Sagar, M. K. Dahlgren, M. T. Racine, R. T. Smith et al., Splendor in the Grass? A Pilot Study Assessing the Impact of Medical Marijuana on Executive Function, Frontiers in pharmacology, vol.7, p.355, 2016.

A. E. Reiman, Self-efficacy, social support and service integration at medical cannabis facilities in the San Francisco Bay area of California, Health & social care in the community, vol.16, pp.31-41, 2008.

M. O. Bonn-miller, K. A. Babson, and R. Vandrey, Using cannabis to help you sleep: heightened frequency of medical cannabis use among those with PTSD. Drug and alcohol dependence, vol.136, pp.162-167, 2014.

B. Wilsey, J. H. Atkinson, M. Td, and G. I. , The Medicinal Cannabis Treatment Agreement: Providing Information to Chronic Pain Patients Through a Written Document, The Clinical journal of pain, vol.31, pp.1087-96, 2015.

P. Hakkarainen, V. A. Frank, and M. J. Barratt, Growing medicine: small-scale cannabis cultivation for medical purposes in six different countries, The International journal on drug policy, vol.26, pp.250-256, 2015.

J. N. Ablin, O. Elkayam, and M. A. Fitzcharles, Attitudes of Israeli Rheumatologists to the Use of Medical Cannabis as Therapy for Rheumatic Disorders, Rambam Maimonides medical journal, vol.7, 2016.

S. S. Martins, C. M. Mauro, and J. Santaella-tenorio, State-level medical marijuana laws, marijuana use and perceived availability of marijuana among the general U.S. population. Drug and alcohol dependence, vol.169, pp.26-32, 2016.

M. A. Bachhuber, B. Saloner, C. Co, and C. L. Barry, Medical cannabis laws and opioid analgesic overdose mortality in the United States, JAMA internal medicine, vol.174, pp.1668-73, 1999.

C. Thomas and B. Freisthler, Examining the locations of medical marijuana dispensaries in Los Angeles. Drug and alcohol review, vol.35, pp.334-341, 2016.

N. Zaller, A. Topletz, S. Frater, G. Yates, and M. Lally, Profiles of medicinal cannabis patients attending compassion centers in rhode island, Journal of psychoactive drugs, vol.47, pp.18-23, 2015.

A. Pesce, C. West, and M. Rosenthal, Marijuana correlates with use of other illicit drugs in a pain patient population, Pain physician, vol.13, pp.283-290, 2010.

J. M. Davis, B. Mendelson, J. J. Berkes, K. Suleta, C. Kf et al., Public Health Effects of Medical Marijuana Legalization in Colorado. American journal of preventive medicine, vol.50, pp.373-382, 2016.

D. Fuster, D. M. Cheng, D. Allensworth-davies, T. P. Palfai, J. H. Samet et al., No detectable association between frequency of marijuana use and health or healthcare utilization among primary care patients who screen positive for drug use, Journal of general internal medicine, vol.29, pp.133-142, 2014.

N. D. Volkow, R. D. Baler, W. M. Compton, and S. R. Weiss, Adverse health effects of marijuana use. The New England journal of medicine, vol.370, pp.2219-2246, 2014.

P. Roy-byrne, C. Maynard, and K. Bumgardner, Are medical marijuana users different from recreational users? The view from primary care, The American journal on addictions, vol.24, pp.599-606, 2015.

A. C. Bradford and W. D. Bradford, Medical Marijuana Laws Reduce Prescription Medication Use In Medicare Part D. Health affairs, vol.35, pp.1230-1236, 2016.

A. C. Ogborne, R. G. Smart, and E. M. Adlaf, Self-reported medical use of marijuana: a survey of the general population, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, vol.162, pp.1685-1691, 2000.

D. N. Juurlink, Medicinal cannabis: time to lighten up?, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, vol.186, pp.897-905, 2014.

H. St-amant, M. A. Ware, J. N. Lacasse, and A. , Prevalence and determinants of cannabinoid prescription for the management of chronic noncancer pain: a postal survey of physicians in the Abitibi-Temiscamingue region of Quebec, CMAJ open, vol.3, pp.251-258, 2015.

L. P. Walsh and Z. , Medical cannabis access, use, and substitution for prescription opioids and other substances: A survey of authorized medical cannabis patients. The International journal on drug policy, vol.42, pp.30-35, 2017.

W. Pedersen and S. Sandberg, The medicalisation of revolt: a sociological analysis of medical cannabis users, Sociology of health & illness, vol.35, pp.17-32, 2013.

R. W. Gorter, M. Butorac, C. Ep, and W. Van-der-sluis, Medical use of cannabis in the Netherlands, Neurology, vol.64, pp.917-926, 2005.

H. Heerdink and E. R. , The prevalence and incidence of medicinal cannabis on prescription in The Netherlands, European journal of clinical pharmacology, vol.69, pp.1575-80, 2013.

K. B. Svendsen, T. S. Jensen, and F. W. Bach, Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial, 253. ANNEXES Annexe, vol.329, 2004.